profile the international therapeutics that move with DUDsworldwide B14 cant increase inheroin andfentanyl use, accounted alone, themisuseofopioids, together withasignifi use disorders theUnited States (DUDs)worldwide. In associatedof thenegative withdrug healthimpact life12 million disability-adjusted years (DALYs), or70% accountingfor drugsinthiscontext, most harmful as aresult ofpremature deathanddisability. mated 28 millionyears ofhealthy life lostworldwide causedby drugusetranslatedthe harm into anesti 2015alone, consumptionofdrugs.in high-risk In 0.6% oftheglobaladultpopulation,were engaged at leastonce( adult populationaged15–64years, usedillicitdrugs 255 million people, orapproximately 5%oftheglobal awareness ofthescaledruguseglobally of thefirst to raiseinternational World DrugReport ognized andtreated. to achronichuman crisis diseasethatshouldberec transform from theperception aglobal ofaddiction treatment. Indivior’s addiction goal istomodern treatment models that have helped revolutionize invested ineducationprograms onevidence-based and schizophrenia. Allalong, thecompany hasalso includingalcoholusedisorderaddiction, (AUD) disorders of chronic conditions and co-occurring a pipelineofproduct candidates to address other folio oftreatments for opioidusedisorder (OUD) and andhealthpolicy,advocacy hasbuiltaglobalport pany ofleadershipinpatient witha20-year legacy com pharmaceutical aglobalspecialty Inc., Indivior treatmentquality for the chronic relapsing conditions disorders of addiction. and co-occurring worldwidemedicine, to andinpartnerships realize its vision that all patients will have access to Indivior is investing in research and development to pioneer life-transforming treatments in addiction medicine innovationDriving addiction in www.indivior.com Inc. Indivior life and well-being improve of theirquality is totally dedicated to the options that helppatients closer to new treatment community onestep development ofinnovative “ Opioids (opiates andprescription opioids)were the The 20 year 2017 marks |November 2017 | and development Indivior’s research Fig. 1 ). Of these, 29.5 millionpeople,). Of or Christian Heidbreder, CSO

biopharmadealmakers.nature.com years since the publication 1 . In 2015, . In - - - - - ©

2 0 ment for OUD. receptor antagonist, for patientssince1996asatreat agonistandκ-opioid receptor (MOR)partial µ-opioid andsupplying buprenorphine, ain manufacturing andhasbeen involvedtion treatment community theaddic ofsupporting hasalonghistory Indivior tion inthefaceofgrowing crisis. globaladdiction development (R&D)thatadvancestreatment innova needs to drivedecisions—incentivizes research and onpatientIndivior’s core guidingprinciple—focus disorder challenge Addressing the drug use of life andwell-being.” patients with DUDs worldwide improve their quality one step closerto treatment new optionsthathelp therapeutics thatmove community theinternational totally dedicated to thedevelopment ofinnovative solutions. Indivior’s research anddevelopment is thatrequireslic healthcrisis scientific pioneering This figure shows therapidlyevolving pub clearly tocan beattributed theuseandmisuseofopioids. “approximately 200,000premature deathsworldwide receives treatment. currently fewer thanoneinsixpersonswithDUDs DUDs andrelated conditionsremains limited, and the1999–2015period. during increased innumberfrom 16,849to 52,404annually United States were mostly driven by opioids and drug-related deathsin2015.Overdose deathsinthe for approximately 25%oftheestimated numberof according onDrugsandCrime to theUnited NationsOffice and prescription opioids),amphetaminesandprescription stimulants, andecstasyisatanall-timehigh Figure 1:Globalprevalence ofdruguseby region. 1 (individuals inmillions) Drug use According Heidbreder, to Christian CSOofIndivior, Despite thisstate ofaffairs, accessto treatment of 7

M Ecstasy Amphetamines Opioids Cocaine a c m i l l a n

P u b l i s h 8.50 e Americas r s

14.71 L i m 7.50 i t e d 3.37 .

A l l

R i g h t s

R e s e r - - - - v 4.06 2.84 e Consumption ofcannabis, cocaine, opioids(opiates d Europe Africa . 4.52 2.13 ADVERTISER RETAINS FORCONTENTADVERTISER SOLERESPONSIBILITY high and sustained MOR occupancy in the brain over high and sustainedMORoccupancy plasma levels ofbuprenorphine thattranslate into ( by diffusionasthe polymer biodegradesperiod depot releases buprenorphine over aone-month and forms soliddepot anamorphous whichtraps buprenorphine insidepolymerization, triggering as it diffuses outof the polymer matrix, withbodyfluidsthatreplaceNMP interacts theNMP compatible solvent. After subcutaneousinjection, in dissolved co-polymer poly-(DL-lactide-co-glycolide) solutionofabiodegradableconsists ofapolymeric tion thatusestheATRIGEL system, which delivery tional buprenorphine sustained-release formula isdeveloping RBP-6000,Indivior investiga anew treatment disorder use access to opioid Expanding R&DCentre ofExcellence inHull, UK. the-art recently invested ofastate-of- intheconstruction of clinicalresponse. To thispromise, has keep Indivior measurements methodologiesand new to support the development ofnovel approaches to treatment to promotemechanistic understandingofaddiction tion. Indivior’s science is constantlyexpandingthe overdose, andtreating ofaddic thecomorbidities diversion and misuse, improving management of treatment adherence andretention, decreasing delivery, decreasing dosingfrequency, increasing define thecompany’s R&Dmission: stabilizingdrug Fig. 2 RBP-6000 was designed to provide sustained Indivior’s focus on putting the patient first helps 5.90 1 2.46 N . -methyl pyrrolidone (NMP), a water-miscible bio 3.75 1.43 ). 1.30 12.95 Asia 20.69 12.49 ADVERTISEMENT FEATUREADVERTISEMENT related deaths, 2015 190,900 estimated drug- Cocaine: 17 million 22million Ecstasy: Amphetamines: 37million Opioids: 35million Cannabis: 183million drug useglobally, 2015 Annual prevalence of 0.39 Oceania 0.75 0.48 in situ 0.61 . The - - - - ©

2 0 1 7

M a c m i l l a n

P u b l i s h e r s

L i m i t e d .

A l l

R i g h t s

R e s e r v e d . ©

2 0 1 7

M a c m i l l a n

P u b l i s h e r s

L i m i t e d .

A l l

R i g h t s

R e s e r v e d . plasma. of an Results ongoing phase less frequent dosingandreduced inthe fluctuations bybe well thelarge absorbed intestine, thusallowing baclofenof thetwo enantiomers, thatisdesigned to prodrug of transported isdeveloping arbaclofen placarbil, anovelIndivior get theGABAsystem ofdrugssuchasbaclofencharacterization thattar (GABA)-mediated neurotransmission, includingthe acid γ-aminobutyric alcohol enhancesinhibitory use ofalcohol. tinued andincreased to reduce efforts theharmful injury DALYs, or5.1%oftheglobalburden ofdiseaseand global deaths, and was responsible for 139 resulted inabout3.3 milliondeaths, or5.9%ofall aged 15 years orolder tion in2016was6.4 Lofpure alcoholperperson averagethe worldwide level ofalcoholconsump drome. According to the World HealthOrganization, potentially life-threatening alcoholwithdrawal syn tolerance, andphysical dependence, of witharisk alcohol craving, lossofcontrol ofalcoholintake, byology thatischaracterized excessive drinking, AUD eti isachronic diseasewithamultifactorial disorder challenge use alcohol the Addressing reactions.injection-site transmucosal buprenorphine, withtheadditionof RBP-6000 profile of was consistent withtheknown withdrawal, andopioidcraving. The safety profile of MOR occupancy,tration, whole-brain abstinence, correlation amongbuprenorphine plasmaconcen Furthermore, analysespredicted exposure-response ing control ofcraving andwithdrawal symptoms. consistent across otherclinicalendpoints, includ over a6-monthperiod. Treatment outcomes were reduced illicitopioidusecompared to placebo showed thattreatment withRBP-6000 significantly that includedcounselingandpsychosocial support of a completesevere treatment OUD as part plan withmoderate to insubjects otal USphase 3trial Drug Administration. The results ofIndivior’s piv and is currently under review by theUS Food and of opioidagonists. toms and reduce the subjective and objective effects to suppress period withdrawal symp a one-month ADVERTISER RETAINS FORCONTENTADVERTISER SOLERESPONSIBILITY 2018. available inearly willbe ofarbaclofenof thebioavailability placarbil and accelerate the allow usto understand and collaborations that medications patients’ unmetneeds development ofnew “ ADVERTISEMENT FEATUREADVERTISEMENT Decades ofresearchDecades have focused ontheway RBP-6000 Designation wasgranted Review Priority 2 . These findingshighlighttheneedfor con are partnerships are partnerships Equally important Equally important Christian Heidbreder, CSO 3 . True to itsvision andmission, 2 . This alcohol consumption R -baclofen, the more active 1/2 clinical study

million ------©

2 Buprenorphine trappedinsidethepolymerformed polymerization. withbodyfluidsthatreplace triggering NMPinteracts theNMPinmatrix, injection, dissolved in ATRIGEL co-polymer system, asolutionconsistingofbiodegradable poly-(DL-lactide-co-glycolide) delivery Figure 2:Indivior’s RBP-6000 sustained-release formulation ofbuprenorphine. be usefulacross DUDs. involvednisms of action in craving; these are to likely also focusing moleculartargets onnew withmecha is bid druguseandpsychiatric associations).Indivior status and health insurance, and decreases in comor resource utilization,improvement inemployment life, decreased healthcare medicationsatisfaction, ment inhealthstatusandhealth-related of quality andsafety (e.g.,beyond clinicalefficacy improve ment plans to better understand patient outcomes and outcomes ofclinicaldevelop research aspart to meetunmetpatientneeds. areas can expand and addiction into which Indivior DUDs also means that there are many more countries that treatment isavailable. The globalchallengeof suretreatment patientsknow optionsandmaking treatments by educatinghealthcare professionals on to contributes wideningaccessto quality Indivior marginalized conditions to treatable diseases. attitudes toward DUDs, revising their status from continues the work of changing societalIndivior patients of behalf on opportunities treatment Expanding treatment period toms ofacute schizophrenia over aneight-week showed clinicallysignificant inthesymp reductions RBP-7000 withacute schizophrenia insubjects to assesstheefficacy,trial safety of and tolerability ment ofschizophrenia. The results ofapivotal phase 3 the ATRIGEL system for treat thelong-term delivery release (RBP-7000) formulation ofrisperidone using DUDs.tially facilitatingthemanagementofcomorbid ance, thereby reducing ofrelapse therisk andpoten may facilitate improvements inmedicationcompli antipsychotics injectable treatment, andlong-acting of aspect antipsychotic is akey pharmacotherapy DUDs have co-occurring posed onchronically poorpsychosocial adjustment, lifelong of acute pattern psychotic episodes superim schizophrenia, a chronic disorder by characterized a For example, halfofpatientsdiagnosed nearly with disorderspsychiatric are withDUDs. highlycomorbid Epidemiological and clinical studies have shown that psychiatric comorbidities Addressing drug use disorder the polymerbiodegrades. 0

Indivior investsIndivior inprospective health economics sustained- isdeveloping aonce-monthly Indivior Plasma level 1 0 7

M a Injected c liquid m 2 i N l l Drug Day a -methyl pyrrolidone (NMP),awater-miscible biocompatiblesolvent. After subcutaneous out n

P 5 . u 4 Solvent Water b l out i in s h e r 4 6 s . Therefore, adherence to

L i m i t e d .

A Plasma level solidification 0 l l

at surface Polymer R i g h t s 2

R Day e s e ------in situ r v 4 e d duration, concurrent medicationsuse)andhow to apy response (e.g., efficacy, nonadherence, treatment ing how to andquantifypharmacother characterize of DUDs,on the pharmacogenomics including learn 5. 4. 3. 2. 1. bidities. Patients are waiting.” ultimately prevent andtreat DUDsandtheircomor coordinated to offer efforts innovative solutions and medications. Indivior’s missionisto facilitate these needs and accelerate the development of new tions thatallow usto understandpatients’ unmet and collabora are“Equally partnerships important neurobiological underpinnings,” said Heidbreder. nature of DUDs require a deep understanding of their life andwell-being of patients withDUDs. with the abuse ofdrugs and improving of the quality patient, thereby preventing future associated harms in thereduction andcessationofdruguseby the may ultimately result efforts that theseconcerted believes nosis, illnesscourse, Indivior comorbidities). define patients’ (e.g., characteristics differential diag . is gradually released over a one-month period as as isgradually period released over aone-month biopharmadealmakers.nature.com |November 2017 | More collaborative research will be required efforts “The inherent complexity and multi-dimensional inherent andmulti-dimensional complexity “The Nasser, A.F. S.M. Hartz, http://dx.doi.org/10.1002/14651858.CD012557 (2017). S.,Minozzi, Saulle, R. & Rösner, S. HealthOrganization, 2017). (World Monitoring Health for the SDGs, Goals Sustainable Development World HealthOrganization. 2017: Executive Summary onDrugsandCrime.United Nations Office contact 6 Email: [email protected] Tel: +1-804-594-4456 USA Virginia, Richmond, Indivior Inc. CSO Heidbreder, Christian Drug out et al et al Plasma level 0 . . JAMA Psychiatry J. Clin. Psychopharmacol. Solvent Water out in (United Nations, 2017). 2 Day

RBP-6000 usesthe World Health Statistics 2017: 71 Cochrane Syst. Rev. Database , 248–254(2014). 4

36 , 130–140(2016). World Report Drug 6 B15 B15 - - - - -

profile